Get the Daily Brief
Latest Biotech News
Tenpoint wins FDA approval: dual‑agent presbyopia drop gets funding
Tenpoint Therapeutics won FDA approval for Yuvezzi, the first dual‑agent eye drop for adult presbyopia combining carbachol and brimonidine, and simultaneously closed financing commitments totaling...
Lilly bets on recombinase editing: Seamless tie could top $1.1B
Eli Lilly struck a global research and licensing agreement with Seamless Therapeutics to apply programmable recombinase gene editing to hearing loss targets, a deal with reported potential value...
Revita procedure cuts weight‑regain after GLP‑1s: 70% reduction
Fractyl Health reported six‑month data from the REMAIN‑1 randomized trial showing its Revita endoscopic procedure reduced post‑GLP‑1 weight regain by roughly 70% versus sham in patients who...
Moderna outlicenses rare‑disease asset: $50M upfront to Recordati
Moderna out‑licensed a late‑stage rare disease candidate to Recordati in a deal that provides $50 million upfront and transfers development responsibilities overseas. The asset could produce...
Eikon sets IPO terms: eyes $317M to advance oncology platform
Eikon Therapeutics filed to raise roughly $317 million in a Nasdaq IPO to accelerate its oncology protein‑dynamics platform and associated drug discovery pipeline. The company, founded by former...
Manufacturing surge: Cellares raises $257M; automaton funding follows
Cellares raised $257 million in a Series D round to accelerate global expansion of its clinical‑stage cell therapy manufacturing services and prepare for a 2027 IPO. The funding will support...
FDA halts Regenxbio AAV trials after patient tumor discovery
The U.S. Food and Drug Administration has placed two Regenxbio gene‑therapy trials on clinical hold after the identification of a brain tumor in a pediatric trial participant. Regenxbio’s programs...
Lilly bets $1.12B on recombinase editing — Seamless deal
Eli Lilly signed a global collaboration and license with Seamless Therapeutics to apply Seamless’s programmable recombinase platform to correct genetic causes of hearing loss. The pact includes up...
Repertoire adds Lilly in near‑$2B autoimmune decode deal
Repertoire Immune Medicines expanded its partner roster with Eli Lilly in a collaboration to develop tolerizing therapies for autoimmune diseases, securing an up‑front payment and potential...
FDA clears Tenpoint’s dual‑agent presbyopia drop; financing follows
Tenpoint Therapeutics won U.S. FDA approval for Yuvezzi, a carbachol‑brimonidine combination ophthalmic solution for adult presbyopia, marking the first dual‑agent drop approved for the...
FDA grants AMT to NanoMosaic — gene‑therapy QC gets regulatory lift
NanoMosaic received Advanced Manufacturing Technology (AMT) designation from the U.S. FDA for its Tessie platform, which quantifies vector genome integrity and capsid titers during AAV...
DeepMind’s AlphaGenome decodes noncoding DNA: variant effects in seconds
DeepMind published AlphaGenome, a long‑sequence DNA model that predicts regulatory activity and the effects of noncoding variants across up to one million base pairs. The Nature paper shows...
Moderna + Merck mRNA‑antibody combo halves melanoma recurrence in interim readout
Interim phase II data from a personalized mRNA neoantigen therapy (intismeran autogene/mRNA‑4157) combined with pembrolizumab showed a roughly 49% reduction in melanoma recurrence and deaths...
Revita endoscopic procedure cuts post‑GLP‑1 weight regain ~70%
Six‑month results from the REMAIN‑1 randomized trial showed Fractyl Health’s Revita procedure reduced weight regain after GLP‑1 discontinuation by roughly 70% versus a sham procedure. The cohort...
Roche trims pipeline after futility finds; flags China diagnostic headwinds
Roche disclosed a program cut after a futility analysis ended a phase 2 fibrosis/inflammation program tied to a Kiniksa asset the company had acquired; Roche said no new safety signals appeared...
DNA‑protein crosslinks activate cGAS‑STING and drive progeroid disease
A Science paper showed that unrepaired DNA‑protein crosslinks (DPCs) accumulate in cells lacking the SPRTN protease, triggering micronuclei formation and activation of the cGAS‑STING innate immune...
FDA halts Regenxbio gene therapy trials — safety scare weeks before approval
The FDA placed Regenxbio’s gene therapy programs on clinical hold after a pediatric trial participant developed a brain tumor, prompting an immediate suspension of two trials and rattling a...
FDA designates NanoMosaic’s Tessie platform as advanced manufacturing tech
The FDA granted Advanced Manufacturing Technology (AMT) designation to NanoMosaic’s Tessie gene therapy QC platform, giving the Waltham, Massachusetts firm prioritized regulatory interactions for...
Lilly inks up‑to‑$1.12B Seamless deal — recombinase editing enters big‑pharma orbit
Eli Lilly agreed to an exclusive research and licensing collaboration with Seamless Therapeutics to apply programmable recombinase gene editing to hearing‑loss targets, in a deal that could reach...
Repertoire lands Lilly collaboration — $1.9B autoimmune programs add Big Pharma backing
Repertoire Immune Medicines added Eli Lilly to its roster of major partners, securing an up‑front payment and potential milestones that push the alliance value toward roughly $1.9–1.92 billion....